Previous 10 | Next 10 |
NetworkNewsWire Editorial Coverage : The emergence of psychedelic therapies as a popular investment a few years ago was mostly underscored by investors that rode the cannabis wave seeing a brand-new opportunity with drugs such as psilocybin, LSD, MDMA, DMT, and others to address hard-to-tre...
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced that the first subjects have been dosed in a Phase 1/2a clin...
Gainers: ABCL +19.8%. TCRR +7.4%. ATAI +6.7%. FANG +4.9%. VCYT +4.7%. Losers: KYMR -7.6%. GRTS -5.1%. JNCE -4.4%. GDS -3.4%. AMTX -3.3%. For further details see: ABCL, TCRR, KYMR and GRTS among after hours movers
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 15, 2021 – The damage done by the opioid epidemic has caused families grief and loss, but recent developments in the case against Purdue Pharma will see some restitution fo...
NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has entered into an amended and restated loan agreement (“...
NEW YORK and BERLIN, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced the initiation of a Phase 2a clinical study to ev...
BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its digital therapeutic platform Introspect Digital Therapeutic...
BERLIN, Sept. 03, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in in the following upcoming inves...
Atai Life Sciences N.V. (ATAI) Q2 2021 Earnings Conference Call August 16, 2021 08:30 ET Company Participants Greg Weaver - Chief Financial Officer Florian Brand - Chief Executive Officer Srinivas Rao - Co-Founder & Chief Scientific Officer Christian Angermayer - Founder & Chairman Co...
-Successfully completed Initial Public Offering on Nasdaq raising $258.8 million in gross proceeds, including the underwriters’ over-allotment- -Received $20 million upfront payment from Otsuka as part of the first major collaboration between a biopharmaceutical company d...
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
Alcohol use disorder is a disorder characterized by an inability to stop or control one’s drinking despite adverse health, occupational or social consequences. Conventional treatments include medication, behavioral therapy, and support groups. Even with these treatments, however, many ind...
Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...